Skip to main content
Erschienen in: International Journal of Hematology 1/2010

01.07.2010 | Special Note

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party

verfasst von: Jae Hoon Lee, Dong Soon Lee, Je Jung Lee, Yoon Hwan Chang, Jong Youl Jin, Deog-Yeon Jo, Soo Mee Bang, Hyo Jung Kim, Jin Seok Kim, Kihyun Kim, Hyeon Seok Eom, Chang Ki Min, Sung Soo Yoon, Sun Hee Kim, Cheolwon Suh, Kyung Sam Cho, the Korean Multiple Myeloma Working Party (KMMWP)

Erschienen in: International Journal of Hematology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Excerpt

The incidence of multiple myeloma suggests an ethnic difference. Compared to Caucasians, who have an incidence rate of 3–5/100,000, Asians show much lower incidence rate compared to them, in the range of 0.5–3/100,000. In Korea, The very first case report of multiple myeloma was published in 1959 [1], and was followed by a few case reports until the 1970s. Since that time, the number of cases of multiple myeloma in Korea increased steadily, reaching 100 cases/year in 1990 [2] and 500 cases/year in 2000 [3], and it is still going up. Currently in Korea, 1,000 patients are estimated to be diagnosed with multiple myeloma, and 700 patients are assumed to die of this disease every year, and 4,000–5,000 patients are suffering from this disease [4]. The most updated, age-standardized, incidence rate of multiple myeloma in Korea is 1.4/100,000, and ranked as the third most common among the hematologic malignancies, only surpassed by non-Hodgkin’s lymphoma and acute myeloid leukemia [5]. Besides, the mortality from multiple myeloma has remarkably increased compared with the mortalities from the other hematologic malignancies, such as leukemia and lymphoma. Indeed, the incidence and mortality of multiple myeloma in Korea have increased more than 30 times during past 30 years [5] (Fig. 1). This unprecedented phenomenon could be explained in two ways. The first one is an increased detection. Expanding medical insurance coverage increased routine checks, and increased awareness of this disease could partly explain in the increased detection, especially in early period of 1980s. The second explanation is a true increase in the incidence of multiple myeloma. Air pollution, and increased exposure to potential carcinogens and radiation are all associated with rapid industrialization, and are suspected as reasons for the increased incidence of multiple myeloma. Another possible reason for the increase is the aging of the Korean population. Koreans have experienced a 17-year median life span over the past 33 years. Since the year of 2,000, Koreans entered an aging society and are heading to an aged society in the year 2020. Moreover, the speed of aging in Korea is known to be fastest in the world. Thus, in the future, we expect more increasing aged population and the incidence of multiple myeloma, considering Japanese model [5]. The median age of the patients with multiple myeloma also increased from mid-fifties in 1980s to 66 years in 2007 [3].
Literatur
1.
Zurück zum Zitat Lee H, Lee M. A case of alpha2 plasmacytoma. New Med J. 1959;2:1113–7. Lee H, Lee M. A case of alpha2 plasmacytoma. New Med J. 1959;2:1113–7.
2.
Zurück zum Zitat Yang SH, Kim TY, Kim BK, Koh YW, Kwak DS, Kim NK, et al. A statistical study of multiple myeloma in Korea. Korean J Hematol. 1995;30:345–61. Yang SH, Kim TY, Kim BK, Koh YW, Kwak DS, Kim NK, et al. A statistical study of multiple myeloma in Korea. Korean J Hematol. 1995;30:345–61.
5.
Zurück zum Zitat Lee JH, Bang SM. Epidemiological changes of multiple myeloma in Korea. Korean J Hematol. 2006;41:225–34.CrossRef Lee JH, Bang SM. Epidemiological changes of multiple myeloma in Korea. Korean J Hematol. 2006;41:225–34.CrossRef
6.
Zurück zum Zitat Kang DY, Lee DI, Kim KH, Kim DJ, Kim BS, Kim SI, et al. Statistical studies on multiple myeloma in Korea—preliminary report. Korean J Hematol. 1972;7:31–40. Kang DY, Lee DI, Kim KH, Kim DJ, Kim BS, Kim SI, et al. Statistical studies on multiple myeloma in Korea—preliminary report. Korean J Hematol. 1972;7:31–40.
7.
Zurück zum Zitat Kim HJ, Heo DS, Bang YJ, Lee SJ, Choi DH, Park S, et al. Multiple myeloma in Korea—clinical analysis and treatment results in 61 cases. Korean J Int Med. 1984;28:770–8. Kim HJ, Heo DS, Bang YJ, Lee SJ, Choi DH, Park S, et al. Multiple myeloma in Korea—clinical analysis and treatment results in 61 cases. Korean J Int Med. 1984;28:770–8.
8.
Zurück zum Zitat Kim TY, Heo DS, Bang YJ, Park S, Kim BK, Kim NK, et al. Combination chemotherapy with vincristine, melphalan and prednisone for multiple myeloma. Korean J Int Med. 1993;45:1–12. Kim TY, Heo DS, Bang YJ, Park S, Kim BK, Kim NK, et al. Combination chemotherapy with vincristine, melphalan and prednisone for multiple myeloma. Korean J Int Med. 1993;45:1–12.
9.
Zurück zum Zitat Kim HJ, Seo CI, Park KC, Kim HT, Heo DS, Bang YJ, et al. Combination chemotherapy for the treatment of multiple myeloma. J Korean Cancer Assoc. 1992;24:577–85. Kim HJ, Seo CI, Park KC, Kim HT, Heo DS, Bang YJ, et al. Combination chemotherapy for the treatment of multiple myeloma. J Korean Cancer Assoc. 1992;24:577–85.
10.
Zurück zum Zitat Jung JW, Kim JH, Kim SY, Yoon HJ, Cho KS. A clinical study on multiple myeloma. J Korean Cancer Assoc. 1995;27:869–78. Jung JW, Kim JH, Kim SY, Yoon HJ, Cho KS. A clinical study on multiple myeloma. J Korean Cancer Assoc. 1995;27:869–78.
11.
Zurück zum Zitat Lee JT, Kim IH, Ahn JS, Lee KH, Kim TY, Park YI, et al. Phase II trial of VAD (vincristine, doxorubicin, and dexamethasone) in refractory multiple myeloma. Korean J Hematol. 1996;31:145–53. Lee JT, Kim IH, Ahn JS, Lee KH, Kim TY, Park YI, et al. Phase II trial of VAD (vincristine, doxorubicin, and dexamethasone) in refractory multiple myeloma. Korean J Hematol. 1996;31:145–53.
12.
Zurück zum Zitat Lee EJ, Lee KH, Hyun MS. Clinical characteristics and therapeutic results in multiple myeloma. Korean J Hematol. 1997;32:409–18. Lee EJ, Lee KH, Hyun MS. Clinical characteristics and therapeutic results in multiple myeloma. Korean J Hematol. 1997;32:409–18.
13.
Zurück zum Zitat Kim SW, Ryoo BY, Kim TY, Im YH, Park YH, Kim BS, et al. A phase II trial of VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for previously untreated multiple myeloma. Korean J Int Med. 1999;56:75–84. Kim SW, Ryoo BY, Kim TY, Im YH, Park YH, Kim BS, et al. A phase II trial of VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for previously untreated multiple myeloma. Korean J Int Med. 1999;56:75–84.
14.
Zurück zum Zitat Lee JH, Bang SM, Lee S, Kim HS, Ahn JS, Cho EK, et al. High dose chemotherapy with autologous stem cell transplantation in multiple myeloma. Korean J of Hematol. 1999;34:306–16. Lee JH, Bang SM, Lee S, Kim HS, Ahn JS, Cho EK, et al. High dose chemotherapy with autologous stem cell transplantation in multiple myeloma. Korean J of Hematol. 1999;34:306–16.
15.
Zurück zum Zitat Bang SM, Lee JH, Yoon SS, Seong JM, Cho KS, Kang YG, et al. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma. J Korean Med Sci. 2003;18:673–8.PubMed Bang SM, Lee JH, Yoon SS, Seong JM, Cho KS, Kang YG, et al. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma. J Korean Med Sci. 2003;18:673–8.PubMed
16.
Zurück zum Zitat Bang SM, Lee JH, Yoon SS, Park S, Lee JJ, Kim HJ, Jo DY, et al. Preliminary report of risk-based approach in Korean patients with newly diagnosed multiple myeloma. Blood. 2004;104:4911. Bang SM, Lee JH, Yoon SS, Park S, Lee JJ, Kim HJ, Jo DY, et al. Preliminary report of risk-based approach in Korean patients with newly diagnosed multiple myeloma. Blood. 2004;104:4911.
17.
Zurück zum Zitat Oh HS, Lee JH, Ahn MJ, Chung CW, Lee SI, Park Q, et al. Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. Int J Hematol. 2002;76:465–70.CrossRefPubMed Oh HS, Lee JH, Ahn MJ, Chung CW, Lee SI, Park Q, et al. Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. Int J Hematol. 2002;76:465–70.CrossRefPubMed
18.
Zurück zum Zitat Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, et al. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma. J Korean Med Sci. 2005;20:598–602.CrossRefPubMed Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, et al. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma. J Korean Med Sci. 2005;20:598–602.CrossRefPubMed
19.
Zurück zum Zitat Kim DY, Im SA, Seong CM, Lee SN, Lee JH, Bang SM, et al. Salvage therapy with thalidomide in patients with multiple myeloma. Korean J Hematol. 2002;37:259–64. Kim DY, Im SA, Seong CM, Lee SN, Lee JH, Bang SM, et al. Salvage therapy with thalidomide in patients with multiple myeloma. Korean J Hematol. 2002;37:259–64.
20.
Zurück zum Zitat Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, et al. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol. 2006;83:309–13.CrossRefPubMed Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, et al. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol. 2006;83:309–13.CrossRefPubMed
21.
Zurück zum Zitat Kim H, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, et al. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. Biol Blood Marrow Transplant. 2006;12:837–44.CrossRefPubMed Kim H, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, et al. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. Biol Blood Marrow Transplant. 2006;12:837–44.CrossRefPubMed
22.
Zurück zum Zitat Bang SM, Kim YR, Cho HI, Chi HS, Seo EJ, Park CK, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168:124–32.CrossRefPubMed Bang SM, Kim YR, Cho HI, Chi HS, Seo EJ, Park CK, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168:124–32.CrossRefPubMed
23.
Zurück zum Zitat Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, et al. Bortezomib, doxorubicin and dexamethasone (PAD) combination therapy followed by thalidomide and dexamethasone (TD) as a salvage treatment for relapsed multiple myeloma (MM): preliminary analysis of efficacy and safety. the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2010 [Epub ahead of print] (English). Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, et al. Bortezomib, doxorubicin and dexamethasone (PAD) combination therapy followed by thalidomide and dexamethasone (TD) as a salvage treatment for relapsed multiple myeloma (MM): preliminary analysis of efficacy and safety. the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2010 [Epub ahead of print] (English).
24.
Zurück zum Zitat Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol. 2010;89:475–82.CrossRefPubMed Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol. 2010;89:475–82.CrossRefPubMed
25.
Zurück zum Zitat Yoon SS, Kim HJ, Lee JH, Lee DS, Eom HS, Jang JH, et al. Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE®, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: interim results of phase II trial. The Korean Multiple Myeloma Working Party (KMMWP). Blood. 2007;110:952 (ASH Annual Meeting Abstracts). Yoon SS, Kim HJ, Lee JH, Lee DS, Eom HS, Jang JH, et al. Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE®, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: interim results of phase II trial. The Korean Multiple Myeloma Working Party (KMMWP). Blood. 2007;110:952 (ASH Annual Meeting Abstracts).
26.
Zurück zum Zitat Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, et al. Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk. 2010;10:62–7.CrossRefPubMed Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, et al. Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk. 2010;10:62–7.CrossRefPubMed
27.
Zurück zum Zitat Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, et al. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2010;89:489–97.CrossRefPubMed Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, et al. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2010;89:489–97.CrossRefPubMed
28.
Zurück zum Zitat Kang SH, Kim TY, Kim HY, Lee YK, Moon HW, Lee DS, et al. Association of NQO1 polymorphism with multiple myeloma risk in Korea. Korean J Lab Med. 2006;26:71–6.CrossRefPubMed Kang SH, Kim TY, Kim HY, Lee YK, Moon HW, Lee DS, et al. Association of NQO1 polymorphism with multiple myeloma risk in Korea. Korean J Lab Med. 2006;26:71–6.CrossRefPubMed
29.
Zurück zum Zitat Kang SH, Kim TY, Kim HY, Yoon JH, Cho HI, Yoon SS, et al. Protective Role of CYP1A1*2A in the development of multiple myeloma. Acta Hematol. 2008;119:60–4.CrossRef Kang SH, Kim TY, Kim HY, Yoon JH, Cho HI, Yoon SS, et al. Protective Role of CYP1A1*2A in the development of multiple myeloma. Acta Hematol. 2008;119:60–4.CrossRef
30.
Zurück zum Zitat Kim TY, Park J, Oh B, Min HJ, Jeong TS, Lee JH, et al. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br J Haematol. 2009;146:270–81.CrossRefPubMed Kim TY, Park J, Oh B, Min HJ, Jeong TS, Lee JH, et al. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br J Haematol. 2009;146:270–81.CrossRefPubMed
31.
Zurück zum Zitat Min HJ, Kim TY, Oh B, Lee JH, Lee DS. The assessment of IL-6R gene using FISH in MM. Blood. 2007;110:4849 (ASH Annual Meeting Abstracts). Min HJ, Kim TY, Oh B, Lee JH, Lee DS. The assessment of IL-6R gene using FISH in MM. Blood. 2007;110:4849 (ASH Annual Meeting Abstracts).
32.
Zurück zum Zitat Kang SH, Lee DS, Kim TY, Min HJ, Oh B, Cho HI, et al. Methylation profiles of p16, p15 and p14 genes in Korean patients with multiple myeloma. Blood. 2007;110:1504 (ASH Annual Meeting Abstracts). Kang SH, Lee DS, Kim TY, Min HJ, Oh B, Cho HI, et al. Methylation profiles of p16, p15 and p14 genes in Korean patients with multiple myeloma. Blood. 2007;110:1504 (ASH Annual Meeting Abstracts).
33.
Zurück zum Zitat Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, et al. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. Acta Hematol. 2009;122:200–10.CrossRef Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, et al. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. Acta Hematol. 2009;122:200–10.CrossRef
34.
Zurück zum Zitat Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant. 2009;15:463–70.CrossRefPubMed Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant. 2009;15:463–70.CrossRefPubMed
35.
Zurück zum Zitat Min CK, Kim H, Kim K, Kwak JY, Lee ST, Won JH, et al. A multicenter comparison of autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation with tandem autologous stem cell transplantation in multiple myeloma. Blood. 2007;110:940 (ASH Annual Meeting Abstracts). Min CK, Kim H, Kim K, Kwak JY, Lee ST, Won JH, et al. A multicenter comparison of autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation with tandem autologous stem cell transplantation in multiple myeloma. Blood. 2007;110:940 (ASH Annual Meeting Abstracts).
36.
Zurück zum Zitat Sym SJ, Kwak JY, Min CK, Won JH, Lee ST, Kim K, et al. Single and tandem autologous peripheral blood stem cell transplantation for patients with multiple myeloma: a korean multicenter retrospective study. Blood. 2007;110:5132 (ASH Annual Meeting Abstracts). Sym SJ, Kwak JY, Min CK, Won JH, Lee ST, Kim K, et al. Single and tandem autologous peripheral blood stem cell transplantation for patients with multiple myeloma: a korean multicenter retrospective study. Blood. 2007;110:5132 (ASH Annual Meeting Abstracts).
37.
Zurück zum Zitat Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2008;8:237–40.CrossRef Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2008;8:237–40.CrossRef
38.
Zurück zum Zitat Koh Y, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol. 2010;89:201–6.CrossRefPubMed Koh Y, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol. 2010;89:201–6.CrossRefPubMed
39.
Zurück zum Zitat Kim SJ, Kim K, Lee JH, Kim MK, Kwak JY, Ryoo HM, et al. Bortezomib-based induction therapy induces better responses and outcomes of autologous stem cell transplantation in newly diagnosed patients with multiple myeloma: the results of Korean Multiple Myeloma Working Party retrospective study, KMM84. Blood. 2008;112:5184. Kim SJ, Kim K, Lee JH, Kim MK, Kwak JY, Ryoo HM, et al. Bortezomib-based induction therapy induces better responses and outcomes of autologous stem cell transplantation in newly diagnosed patients with multiple myeloma: the results of Korean Multiple Myeloma Working Party retrospective study, KMM84. Blood. 2008;112:5184.
40.
Zurück zum Zitat Bang SM, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, et al. Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. Cancer Genet Cytogenet. 2010;197:117–21.CrossRefPubMed Bang SM, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, et al. Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. Cancer Genet Cytogenet. 2010;197:117–21.CrossRefPubMed
41.
Zurück zum Zitat Lee JJ, Choi BH, Kang HK, Park MS, Park JS, Kim SK, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma. 2007;48:2022–31.CrossRefPubMed Lee JJ, Choi BH, Kang HK, Park MS, Park JS, Kim SK, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma. 2007;48:2022–31.CrossRefPubMed
42.
Zurück zum Zitat Kim SK, Nguyen Pham TN, Nguyen Hoang TM, Kang HK, Jin CJ, Nam JH, et al. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol. 2009;88:1113–23.CrossRefPubMed Kim SK, Nguyen Pham TN, Nguyen Hoang TM, Kang HK, Jin CJ, Nam JH, et al. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol. 2009;88:1113–23.CrossRefPubMed
43.
Zurück zum Zitat Yang DH, Park JS, Jin CJ, Kang HK, Nam JH, Rhee JH, et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res. 2009;33:665–70.CrossRefPubMed Yang DH, Park JS, Jin CJ, Kang HK, Nam JH, Rhee JH, et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res. 2009;33:665–70.CrossRefPubMed
44.
Zurück zum Zitat Yang DH, Kim MH, Hong CY, Lee YK, Jin CJ, Pham TN, et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol. 2010 [Epub ahead of print]. Yang DH, Kim MH, Hong CY, Lee YK, Jin CJ, Pham TN, et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol. 2010 [Epub ahead of print].
45.
Zurück zum Zitat Kim MK, Suh C, Min CK, Kim JS, Kim K, Moon JH, et al. Immunoglobulin D multiple myeloma: clinical presentation, response to therapy and prognostic factors in 75 patients: an analysis of the Korean Multiple Myeloma Working Party (KMMWP). Blood. 2009;114:1792 (ASH Annual Meeting Abstracts). Kim MK, Suh C, Min CK, Kim JS, Kim K, Moon JH, et al. Immunoglobulin D multiple myeloma: clinical presentation, response to therapy and prognostic factors in 75 patients: an analysis of the Korean Multiple Myeloma Working Party (KMMWP). Blood. 2009;114:1792 (ASH Annual Meeting Abstracts).
46.
Zurück zum Zitat Kim HJ, Choi DR, Yun GW, Park EK, Kim SJ, Lee YK, et al. Myelomatous pleural effusion of multiple myeloma: characteristics and outcome. Blood. 2009;114:3874 (ASH Annual Meeting Abstracts). Kim HJ, Choi DR, Yun GW, Park EK, Kim SJ, Lee YK, et al. Myelomatous pleural effusion of multiple myeloma: characteristics and outcome. Blood. 2009;114:3874 (ASH Annual Meeting Abstracts).
47.
Zurück zum Zitat Kim HJ, Shim H, Park EK, Kim MK, Kim SJ, Park JS, et al. Osteonecrosis of the jaw in multiple myeloma patients: incidence and characteristics in Korean patients. Blood. 2009;114:4956 (ASH Annual Meeting Abstracts). Kim HJ, Shim H, Park EK, Kim MK, Kim SJ, Park JS, et al. Osteonecrosis of the jaw in multiple myeloma patients: incidence and characteristics in Korean patients. Blood. 2009;114:4956 (ASH Annual Meeting Abstracts).
48.
Zurück zum Zitat Kim MJ, Oh SJ, Min CK, Park CW, Yoon HJ, Do YR, et al. The prognostic impact of fluorescent-in situ hybridization (FISH) and conventional karyotyping in Korean multiple myeloma patients: a retrospective multicenter study. Blood. 2009;114:4902 (ASH Annual Meeting Abstracts). Kim MJ, Oh SJ, Min CK, Park CW, Yoon HJ, Do YR, et al. The prognostic impact of fluorescent-in situ hybridization (FISH) and conventional karyotyping in Korean multiple myeloma patients: a retrospective multicenter study. Blood. 2009;114:4902 (ASH Annual Meeting Abstracts).
49.
Zurück zum Zitat Min CK, Kim SJ, Lee JJ, Suh C, Kim JS, Yoon SS, et al. The effect of bortezomib on bone metabolism of patients with multiple myeloma: a Korean multicenter prospective study. Blood. 2009;114:4871 (ASH Annual Meeting Abstracts). Min CK, Kim SJ, Lee JJ, Suh C, Kim JS, Yoon SS, et al. The effect of bortezomib on bone metabolism of patients with multiple myeloma: a Korean multicenter prospective study. Blood. 2009;114:4871 (ASH Annual Meeting Abstracts).
50.
Zurück zum Zitat Avet-Loiseau H, Durie BGM, Haessler J, Crowley J, Hoering A, Barlogie B, et al. Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG analysis of 9,897 patients. Blood. 2009;114:743 (ASH Annual Meeting Abstracts). Avet-Loiseau H, Durie BGM, Haessler J, Crowley J, Hoering A, Barlogie B, et al. Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG analysis of 9,897 patients. Blood. 2009;114:743 (ASH Annual Meeting Abstracts).
51.
Zurück zum Zitat Kumar S, Crowley J, Goldschmidt H, Hoering A, Jagannath S, Lahuerta JJ, et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group Study. Blood. 2009;114:2878 (ASH Annual Meeting Abstracts). Kumar S, Crowley J, Goldschmidt H, Hoering A, Jagannath S, Lahuerta JJ, et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group Study. Blood. 2009;114:2878 (ASH Annual Meeting Abstracts).
52.
Zurück zum Zitat Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716–30.CrossRefPubMed Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716–30.CrossRefPubMed
Metadaten
Titel
Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party
verfasst von
Jae Hoon Lee
Dong Soon Lee
Je Jung Lee
Yoon Hwan Chang
Jong Youl Jin
Deog-Yeon Jo
Soo Mee Bang
Hyo Jung Kim
Jin Seok Kim
Kihyun Kim
Hyeon Seok Eom
Chang Ki Min
Sung Soo Yoon
Sun Hee Kim
Cheolwon Suh
Kyung Sam Cho
the Korean Multiple Myeloma Working Party (KMMWP)
Publikationsdatum
01.07.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 1/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0617-6

Weitere Artikel der Ausgabe 1/2010

International Journal of Hematology 1/2010 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.